Clene Inc. Advances ALS Treatment with FDA Meeting and Biomarker Data Analysis
Clene Inc. reports Q2 2025 results, plans FDA meeting for ALS treatment CNM-Au8, and prepares biomarker data analysis, aiming for 2025 NDA submission.
This news is significant for patients suffering from ALS and other neurodegenerative diseases, as it highlights the potential for a new, effective treatment option. The progress of CNM-Au8 through clinical trials and towards FDA approval could offer hope to those affected by these debilitating conditions, marking a pivotal step forward in medical science and patient care.
